glp 1 agonist for type 1 diabetes GLP-1 receptor agonists are increasingly used to treat 2 and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Could GLP-1 Receptor Agonists Help

Few generics are in development

While the recent phase 3 trial for orforglipron was specifically for type 2 diabetes and not weight loss, the study found that patients who took the drug lost considerable weight

This encouraged scientists to begin investigating whether targeting the central nervous system could provide an effective strategy for weight loss (Capozzi, DiMarchi, Tschpp)

Time-restricted eating (limiting food intake to an 8-12 hour window) has shown some metabolic benefits in small studies, but mechanisms are not fully established and may involve multiple hormonal pathways

We need to better understand how the dosing and dose intervals affect all of the above risks and results, says Snyder